Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients

NCT07366658 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

SCLC, Extensive Stage
Neuroendocrine Tumors

Interventions

BIOLOGICAL: Biological/Vaccine: NK Cell Therapy Product Derived from Induced Pluripotent Stem Cells (iPSCs) Engineered with Anti-DLL3 CAR Construct, Followed by Differentiation and Expansion

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

Neukio Biotherapeutics (Shanghai) Co., Ltd.